Aristotle Atlantic’s Core Equity Strategy Sold Becton, Dickinson and Company (BDX) Due to Recent Earnings Weakness

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and attribution analysis. A copy of the letter can be downloaded here. In the quarter, the US equity market rallied, with the S&P 500 Index reaching 8.12%. Bonds also finished higher in the period, with the Bloomberg U.S. Aggregate Bond Index increasing 2.03%. The composite has returned 7.22% gross of fees (7.10% net of fees) in the quarter, underperforming the S&P 500 Index’s 8.12% gain. Security selection led to the relative underperformance of the strategy in the quarter. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Aristotle Atlantic Core Equity Strategy highlighted stocks such as Becton, Dickinson and Company (NYSE:BDX). Becton, Dickinson and Company (NYSE:BDX) is a healthcare company that develops and manufactures medical supplies, devices, laboratory equipment, and diagnostic products. The one-month return of Becton, Dickinson and Company (NYSE:BDX) was 1.07%, and its shares lost 13.86% of their value over the last 52 weeks. On November 14, 2025, Becton, Dickinson and Company (NYSE:BDX) stock closed at $193.04 per share, with a market capitalization of $55.33 billion.

Aristotle Atlantic Core Equity Strategy stated the following regarding Becton, Dickinson and Company (NYSE:BDX) in its third quarter 2025 investor letter:

“We sold Becton, Dickinson and Company (NYSE:BDX) following weakness related to its recent fiscal earnings quarter, where results showed impact from cuts to certain programs funded by the National Institutes of Health (NIH). The company cut forward earnings and revenue guidance to reflect weakness in funding for biosciences research and development (R&D) and the expected impacts of tariffs. While Becton is attempting to divest its Biosciences and Diagnostic Solutions divisions, we are not confident that it will attain the best value given the cyclical downturn affecting these businesses. We believe it will take time for Becton to regain investor confidence and expand the company’s valuation.”

Is Becton, Dickinson, and Company (BDX) the Best-Falling Stock to Buy According to Analysts?

Becton, Dickinson and Company (NYSE:BDX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 58 hedge fund portfolios held Becton, Dickinson and Company (NYSE:BDX) at the end of the second quarter, up from 54 in the previous quarter. In the fiscal fourth quarter of 2025, Becton, Dickinson and Company’s (NYSE:BDX) revenue grew 7% to $5.9 billion or 3.9% organic. While we acknowledge the risk and potential of Becton, Dickinson and Company (NYSE:BDX) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Becton, Dickinson and Company (NYSE:BDX) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Becton, Dickinson and Company (NYSE:BDX) and shared FMI’s views on the company. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.